A non-gene edited approach to allogeneic CAR-T development

admin_vjr_user — Sat, 10 Apr 2021 10:58:00 +0000

Filippo Petti, CEO/CFO, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the benefits of using a non-gene edited approach for the development of single-vector, allogeneic CAR-T cancer therapies. Preliminary data from the ongoing Phase I alloSHRINK study (NCT03692429) in patients with colorectal cancer treated with CYAD-101, a natural killer group 2D (NKG2D) CAR-T candidate encoding the T cell receptor inhibitory molecule (TIM), has highlighted the potential of this approach. He also introduces the recently launched Phase I IMMUNICY-1 study (NCT04613557) investigating CYAD-211, a short hairpin RNA (shRNA)-based CAR T therapy, in patients with multiple myeloma. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

admin_vjr_user — Wed, 10 Mar 2021 19:30:16 +0000

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 CYCLE-1 dose-escalation study (NCT04167696) of CYAD-02, an investigational autologous CAR-T cell therapy that is engineered to express both the natural killer group 2D (NKG2D) receptor and short hairpin RNA (shRNA), in patients with relapsed/refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS). This study aims to determine the recommended dose of CYAD-02 and evaluate safety and clinical activity of a single infusion of CYAD-02 following preconditioning chemotherapy in patients with r/r AML or MDS. This interview took place during the CAR-TCR Summit Europe 2021.

CYAD-01 – VJRegenMed

A non-gene edited approach to allogeneic CAR-T development

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS